ORENCIA® (abatacept) demonstrates comparable efficacy to Humira® (adalimumab)
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a head-to-head clinical trial of 646 patients comparing the subcutaneous (SC) formulation of ORENCIA® (abatacept) vs. Humira® (adalimumab),
Trastuzumab emtansine (T-DM1) reduced the risk of cancer worsening or death
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint, of a significant improvement in the time patients with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival; PFS).
Boehringer Ingelheim expands development capacities with new technical centre
- Details
- Category: Boehringer Ingelheim
The research driven pharmaceutical company Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility for the production of newly developed active pharmaceutical ingredients. The company announced this investment in its largest research and development site worldwide in Biberach, Germany.
UCB expands in Brazil
- Details
- Category: UCB
UCB (Euronext Brussels: UCB) and Meizler Biopharma, a privately-owned Brazilian pharmaceutical company, have signed an agreement by which UCB acquires 51% of Meizler Biopharma. The agreement foresees performance related milestone payments in the coming years as well as an option to purchase the remaining 49% later in time.
Genzyme recognizes World MS Day
- Details
- Category: Genzyme
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), marked World MS Day with activities across its global network and new programs designed to mobilize and inspire people living with multiple sclerosis.
Bristol-Myers Squibb announces global collaboration with leading academic institutions
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology.
Lundbeck's Lu AE58054 meets primary endpoint
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announced that Lu AE58054 has met its primary endpoint in a fixed dose, randomized, placebo-controlled clinical study in 278 patients suffering from Alzheimer's disease.
More Pharma News ...
- Innovative public-private collaboration launches to tackle antibiotic research
- Bayer's Regorafenib submitted for EU and US marketing authorization
- One million signatures needed to call upon World Health Organisation
- Roche will report new data on important progress for people with advanced cancers at ASCO 2012
- Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
- Merck total revenues increase 3.2% to € 2.6 billion
- Pfizer provides topline results from Phase 3 study of Torisel®